Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis

Published:2017-07-31 Issue:10 Volume:20 Page:1056-1065
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Yang Hongbo¹,Duchesneau Emilie¹,Foster Rebekah²,Guerin Annie³,Ma Esprit⁴,Thomas Nina P.⁴

Affiliation:

1. Analysis Group, Inc., Boston, MA, USA;

2. Analysis Group, Inc., New York, NY, USA;

3. Analysis Group, Inc., Montreal, QC, Canada;

4. Genentech Inc., South San Francisco, CA, USA

Funder

Genentech

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1355310

Reference42 articles.

1. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging

2. Multiple sclerosis

3. Multiple sclerosis—a quiet revolution

4. National Multiple Sclerosis Society [Internet]. MS symptoms. 2016. http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed October 2016

5. HealthLine [Internet]. Multiple sclerosis by the numbers: facts, statistics, and you. 2015. http://www.healthline.com/health/multiple-sclerosis/facts-statistics-infographic. Accessed October 2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis;Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques;2024-05-23

2. Benefit of clinical pharmacists in neurology clinics at an academic medical center;Journal of the American Pharmacists Association;2024-03

3. Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada;Journal of Comparative Effectiveness Research;2023-09

4. Cost-Utility Analysis Comparing Ocrelizumab Versus Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective;Value in Health Regional Issues;2023-07

5. Ocrelizumab for the treatment of relapsing remitting multiple sclerosis: A cost effectiveness study in Peru;2023-06-29